Inventage Lab Inc is a Korea-based company principally engaged in the pharmaceutical business. The Company owns the platforms applied to the development and mass production of long-acting injections and drug delivery of genetic materials. The Company is engaged in the research, manufacture and sale of human medicines used for male pattern baldness, dementia, prostate cancer and others. It is also engaged in the research, manufacture and sale of veterinary medicines such as combination drugs, chemical castration agents and others.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-06-19	42,300.00 ₩	-2.42%	121,932
26-06-18	43,350.00 ₩	-6.37%	89,646
26-06-17	46,300.00 ₩	+0.33%	103,760
26-06-16	46,150.00 ₩	+0.33%	79,503
26-06-15	46,000.00 ₩	+2.56%	76,190

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Korea S.E. Other stock markets 2026-06-19			5-day change	1st Jan Change
42,300.00 ^KRW	-2.42%		-5.69%	-49.76%

03-15	Quratis Inc. announced that it has received KRW 10.000000167 billion in funding from Inventage Lab, Inc.	CI
03-15	Inventage Lab, Inc. announced that it has received KRW 89.99724455 billion in funding from a group of investors	CI

Market Cap	562B 367M 320M 296M 277M 520M 34.62B 523M 3.51B 1.36B 17.04B 1.38B 1.35B 59.17B	P/E 2024	-11.5x	P/E 2025	-110x
Enterprise Value	556B 363M 317M 293M 275M 515M 34.29B 518M 3.48B 1.35B 16.88B 1.36B 1.33B 58.6B	EV / Sales 2024	106x	EV / Sales 2025	356x
Free-Float	78.93%	Yield 2024 *	-	Yield 2025	-

03-15	Quratis Inc. announced that it has received KRW 10.000000167 billion in funding from Inventage Lab, Inc.	CI
03-15	Inventage Lab, Inc. announced that it has received KRW 89.99724455 billion in funding from a group of investors	CI
03-08	Inventage Lab, Inc. announced that it has received KRW 8.5 billion in funding	CI
03-05	Inventage Lab, Inc. announced that it expects to receive KRW 37.25 billion in funding from a group of investors	CI
03-05	Inventage Lab, Inc. announced that it expects to receive KRW 8.5 billion in funding	CI
03-05	Inventage Lab, Inc. announced that it expects to receive KRW 52.74724455 billion in funding from a group of investors	CI
03-05	Quratis Inc. announced that it expects to receive KRW 10.000000167 billion in funding from Inventage Lab, Inc.	CI
02-25	Inventage Lab, Inc. agreed to acquire an additional 12.79% stake in Quratis Inc. for KRW 13.5 billion.	CI
12-10	Inventage Lab Seeks Approval for Phase 2 Trial of Alopecia Drug in Australia	MT
25-09-22	Inventage Lab, Inc.(KOSDAQ:A389470) added to S&P Global BMI Index	CI
25-03-11	Inventage Lab, Inc. announced that it has received KRW 9.9999925 billion in funding from PEACE to S KOREA Co., Ltd	CI
25-03-11	Quratis Inc. announced that it has received KRW 10.0329 billion in funding from Inventage Lab, Inc.	CI
25-02-20	Quratis Inc. announced that it has received KRW 15 billion in funding from Inventage Lab, Inc.	CI

1 day	-2.42%
1 week	-5.69%
Current month	-16.90%
1 month	-12.15%
3 months	-47.06%
6 months	-50.93%
Current year	-49.76%

Inventage Lab, Inc. Stock

Stocks

A389470

KR7389470006

Pharmaceuticals

Valuation: Inventage Lab, Inc.

Chart: Inventage Lab, Inc.

Latest news : Inventage Lab, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Inventage Lab, Inc.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	40,650	49,350
1 month	40,100	57,400
Current year	40,100	101,700
1 year	28,550	101,700
3 years	8,800	101,700
5 years	8,440	101,700
10 years	8,440	101,700

Manager	Title	Age	Since
Ju-Hee Kim CEO	Chief Executive Officer	52	2015-05-13
Byeong-Yul Jeong DFI	Director of Finance/CFO	55	-
Chan-Hee Jeon CTO	Chief Tech/Sci/R&D Officer	57	-

Director	Title	Age	Since
Ju-Hee Kim BRD	Director/Board Member	52	2015-05-13
Choong-Ho Ryu BRD	Director/Board Member	56	-
Dong-Hoon Kim BRD	Director/Board Member	56	-

Date	Insider	Type	Quantity	% Market Cap.
25-08-07	Dong Seok Park	Fiscal year	8,000	0.0796%
25-08-07	Dong Seok Park	Fiscal year	8,000	0.0796%
25-08-07	Se Yeon Kim	Fiscal year	10,000	0.0996%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INVENTAGE LAB, INC.	-2.42%	-5.69%	+2.79%	+370.00%	367M
ELI LILLY AND COMPANY	-1.21%	-3.04%	+44.03%	+142.51%	980B
JOHNSON & JOHNSON	-2.48%	-5.18%	+52.47%	+39.36%	550B
ABBVIE INC.	-2.14%	-4.94%	+16.83%	+58.18%	382B
ROCHE HOLDING AG	+0.25%	-3.09%	+23.33%	+16.78%	316B
ASTRAZENECA PLC	+0.61%	-1.69%	+27.35%	+14.22%	272B
NOVARTIS AG	+0.22%	-3.10%	+24.67%	+30.69%	268B
NOVO NORDISK A/S	+4.59%	+1.98%	-38.43%	-46.41%	199B
AMGEN INC.	-1.19%	-4.95%	+16.68%	+48.70%	182B
GILEAD SCIENCES, INC.	-1.35%	-1.46%	+14.06%	+59.46%	154B
Average	-0.51%	-3.52%	+18.38%	+73.35%	330.27B
Weighted average by Cap.	-0.78%	-3.68%	+29.49%	+63.52%

	2024	2025
Net sales	1.78B 1.16M 1.02M 941K 880K 1.65M 110M 1.66M 11.16M 4.32M 54.09M 4.37M 4.28M 188M	2.94B 1.92M 1.67M 1.55M 1.45M 2.72M 181M 2.74M 18.39M 7.13M 89.16M 7.21M 7.05M 310M
Net income	-17B -11.1M -9.68M -8.97M -8.39M -15.74M -1.05B -15.84M -106M -41.22M -516M -41.68M -40.78M -1.79B	-8.46B -5.53M -4.82M -4.46M -4.18M -7.83M -521M -7.88M -52.93M -20.51M -257M -20.74M -20.3M -891M
Net Debt	-23.96B -15.65M -13.65M -12.64M -11.83M -22.19M -1.48B -22.33M -150M -58.12M -727M -58.76M -57.5M -2.52B	-5.33B -3.48M -3.03M -2.81M -2.63M -4.93M -328M -4.96M -33.34M -12.92M -162M -13.06M -12.78M -561M